Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 5/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4596362 | 0.81 | KIF11 (0.61) | CYP11B1CYP11B2PDE3BPDE3AMAOA | |
| SCHEMBL4596680 | 0.77 | KIF11 (0.68) | CYP11B1CYP11B2PDE3BPDE3AKIF11 | |
| SCHEMBL25904133 | 0.76 | CYP11B1 (0.59) | CYP11B1CYP11B2PDE3BPDE3AMAOA | |
| SCHEMBL4897585 | 0.75 | KIF11 (0.58) | CYP11B1CYP11B2PDE3BPDE3AKIF11 | |
| SCHEMBL4888650 | 0.75 | KIF11 (0.67) | CYP11B1CYP11B2PDE3BPDE3AMAOA | |
| SCHEMBL4898364 | 0.75 | CYP11B1 (0.52) | CYP11B1CYP11B2PDE3BPDE3AMAOA | |
| SCHEMBL20262165 | 0.73 | MAOB (0.61) | CYP11B1CYP11B2PDE3BPDE3AMAOA | |
| SCHEMBL14128442 | 0.73 | MAOB (0.57) | CYP11B1CYP11B2PDE3BPDE3AMAOA | |
| SCHEMBL25904981 | 0.72 | MAOB (0.78) | CYP11B1CYP11B2PDE3BPDE3AMAOA | |
| SCHEMBL6754956 | 0.72 | KIF11 (0.68) | CYP11B1CYP11B2PDE3BPDE3AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | claimed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | CYP11B1 780/4885CYP11B2 1046/4885PDE3B 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.